Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) was the recipient of a significant drop in short interest during the month of June. As of June 15th, there was short interest totalling 92,000 shares, a drop of 58.8% from the May 31st total of 223,200 shares. Based on an average trading volume of 1,476,400 shares, the days-to-cover ratio is presently 0.1 days.
Bayer Aktiengesellschaft Stock Up 1.0 %
OTCMKTS:BAYRY traded up $0.07 during mid-day trading on Friday, hitting $7.04. The company had a trading volume of 707,797 shares, compared to its average volume of 748,317. The business has a fifty day simple moving average of $7.48 and a 200-day simple moving average of $7.87. The company has a current ratio of 1.31, a quick ratio of 0.87 and a debt-to-equity ratio of 1.06. Bayer Aktiengesellschaft has a 1 year low of $6.89 and a 1 year high of $14.70.
Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) last announced its earnings results on Tuesday, May 14th. The company reported $0.77 earnings per share (EPS) for the quarter. Bayer Aktiengesellschaft had a positive return on equity of 17.57% and a negative net margin of 6.70%. The business had revenue of $14.95 billion for the quarter. As a group, equities analysts expect that Bayer Aktiengesellschaft will post 1.36 EPS for the current year.
Bayer Aktiengesellschaft Cuts Dividend
Analysts Set New Price Targets
A number of brokerages recently weighed in on BAYRY. Sanford C. Bernstein reiterated a “market perform” rating on shares of Bayer Aktiengesellschaft in a report on Thursday, March 7th. The Goldman Sachs Group started coverage on Bayer Aktiengesellschaft in a research report on Thursday, May 30th. They issued a “neutral” rating on the stock. One analyst has rated the stock with a sell rating and nine have given a hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold”.
Get Our Latest Stock Analysis on Bayer Aktiengesellschaft
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.
Featured Stories
- Five stocks we like better than Bayer Aktiengesellschaft
- What is the S&P 500 and How It is Distinct from Other Indexes
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- 3 REITs to Buy and Hold for the Long Term
- MarketBeat Week in Review – 6/24 – 6/28
- Manufacturing Stocks Investing
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Receive News & Ratings for Bayer Aktiengesellschaft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer Aktiengesellschaft and related companies with MarketBeat.com's FREE daily email newsletter.